Attenuated FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second -line chemotherapy for the Koreans (Asian population) with gemcitabineresistant or -refractory advanced pancreatic cancer.

被引：0
|
作者：
Lee, Sang-Cheol
Kim, Jung Hoon
Oh, Sung Yong
Kim, Kyoungha
Song, Seo-Young
Lee, Namsu
Nam, Eun M. I.
Lee, Soonil
Hwang, In Gyu
Lee, Hyo Rak
Won, jong-Ho
Lee, Kyu Taek
Bae, Sang-Byung
Kim, Hanjo
Kim, Hyun Jung
Jang, JoungSoon
Lim, Do Hyoung
Lee, Hyun Woo
Kang, Jung Hun
机构：
[1] Soonchunhyang Univ Hosp Seoul, Coll Med, Dept Internal Med,Div Hematol Oncol, Seoul, South Korea
[2] Hallym Univ, Chuncheon Sacred Heart Hosp, Div Hematol Oncol, Dept Internal Med, Chunchon, South Korea
[3] Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea
[4] Soonchunhyang Univ Hosp Seoul, Seoul, South Korea
[5] Kangwon Natl Univ Hosp, Sch Med, Dept Internal Med, Chunchon, South Korea
[6] Ewha Womans Univ, Seoul, South Korea
[7] Dankook Univ Hosp, Coll Med, Dept Internal Med, Cheonan, South Korea
[8] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[9] Korea Canc Ctr Hosp, Dept Internal Med, Seoul, South Korea
[10] Soonchunhyang Univ, Cheonan Hosp, Cheonan, South Korea
[11] Soonchunhyang Univ Hosp Cheonan, Cheonan, South Korea
[12] Soonchunhayng Univ, Coll Med, Bucheon Hosp, Bucheon, South Korea
[13] Chung Ang Univ Hosp, Seoul, South Korea
[14] Dankook Univ Hosp, Cheonan, South Korea
[15] Ajou Univ Hosp, Suwon, South Korea
[16] Gyeongsang Natl Univ Hosp, Sch Med, Div Hematol Oncol, Dept Internal Med, Jinju, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15731
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15731
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer
    Lee, S. C.
    Lee, K.
    Bae, S. B.
    Kim, Han Jo
    Oh, S. Y.
    Song, S. Y.
    Hong, D. S.
    Kim, Hyun Jung
    Yoon, J.
    Lim, D. H.
    Lee, S. I.
    Won, J. H.
    Lee, N.
    Kim, K.
    Lee, H. W.
    Lee, H. R.
    Nam, E. M.
    Jang, J. S.
    Hwang, I. G.
    Kang, J. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S456 - S456
  • [2] 5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayar, C.
    Piedbois, P.
    Culine, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] FLUOROURACIL/LEUCOVORIN (5FU/LV) COMBINED WITH IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) AS SECOND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayyar, C.
    Paul, M.
    Culine, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
  • [4] 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.
    Kharofa, Jordan
    Kelly, Tracy R.
    Ritch, Paul S.
    George, Ben
    Wiebe, Lauren Allison
    Thomas, James P.
    Christians, Kathleen K.
    Evans, Douglas B.
    Erickson, Beth
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
    Masi, G
    Allegrini, G
    Marcucci, L
    Cupini, S
    Brunetti, I
    Fontana, E
    Ricci, S
    Cerri, E
    Barbara, C
    Falcone, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [6] Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
    Modest, Dominik Paul
    Heinemann, Volker
    Schuett, Philipp
    Angermeier, Stefan
    Haberkorn, Mike
    Waidmann, Oliver
    Graeven, Ullrich
    Wille, Kai
    Kunzmann, Volker
    Henze, Larissa
    Constantin, Christian
    de Wit, Maike
    Denzlinger, Claudio
    Ballhausen, Alexej
    Kurreck, Annika
    Jelas, Ivan
    Alig, Annabel Helga Sophie
    Stahler, Arndt
    Stintzing, Sebastian
    Oettle, Helmut
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (07)
  • [7] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
  • [8] Weekly oxaliplatin and 5-fluororuracil (5-FU) modulated by leucovorin as second line chemotherapy for pancreatic cancer
    Chiappino, I.
    Novarino, A.
    Addeo, A.
    Bertetto, O.
    ANNALS OF ONCOLOGY, 2005, 16 : 49 - 49
  • [9] FOLFIRINOX versus sequential 5-FU, oxaliplatin, and irinotecan-based regimens in patients with recurrent pancreatic cancer (rPDAC).
    Rehman, Hasan
    Chi, Jeffrey
    Hakim, Nausheen
    Jose, Jyothi
    Moriarty, Linda
    Lamont, Carol
    Saif, Wasif M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)
    Scheithauer, W
    Lathan, B
    Kornek, G
    Raderer, M
    Valencak, J
    Klein, G
    Hejna, M
    Brodovic, T
    Weinlander, G
    Depisch, D
    ANNALS OF ONCOLOGY, 1998, 9 : 172 - 172
12345